MATINAS BIOPHARMA HOLDINGS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $3.00K, a 97.30% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $74.00K, a 32.11% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $91.00K, a 41.67% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $111.00K, a 26.97% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $420.00K, a 30.23% decline from fiscal 2024.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $602.00K, a 9.85% increase from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $548.00K, a 1.11% increase from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $542.00K, a 8.18% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-13 | $77.00K 10-Q · filed 2026-08-13 | $168.00K derived: sum of 3 quarters · filed 2026-08-13 | $279.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $74.00K 10-Q · filed 2026-05-08 | $165.00K derived: sum of 2 quarters · filed 2026-05-08 | $276.00K derived: sum of 3 quarters · filed 2026-05-08 | $387.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $202.00K derived: sum of 2 quarters · filed 2026-03-31 | $313.00K derived: sum of 3 quarters · filed 2026-08-13 | $420.00K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $111.00K 10-Q · filed 2025-11-10 | $222.00K derived: sum of 2 quarters · filed 2026-08-13 | $329.00K 10-Q · filed 2025-11-10 | $487.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $111.00K 10-Q · filed 2026-08-13 | $218.00K 10-Q · filed 2026-08-13 | $376.00K derived: sum of 3 quarters · filed 2026-08-13 | $528.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $109.00K 10-Q · filed 2026-05-08 | $265.00K derived: sum of 2 quarters · filed 2026-05-08 | $417.00K derived: sum of 3 quarters · filed 2026-05-08 | $566.00K derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $308.00K derived: sum of 2 quarters · filed 2026-03-31 | $457.00K derived: sum of 3 quarters · filed 2026-03-31 | $602.00K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $152.00K 10-Q · filed 2025-11-10 | $301.00K derived: sum of 2 quarters · filed 2025-11-10 | $446.00K 10-Q · filed 2025-11-10 | $588.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $149.00K 10-Q · filed 2025-08-14 | $294.00K 10-Q · filed 2025-08-14 | $436.00K derived: sum of 3 quarters · filed 2025-08-14 | $575.00K derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $145.00K 10-Q · filed 2025-05-15 | $287.00K derived: sum of 2 quarters · filed 2025-05-15 | $426.00K derived: sum of 3 quarters · filed 2025-05-15 | $561.00K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $281.00K derived: sum of 2 quarters · filed 2025-04-15 | $416.00K derived: sum of 3 quarters · filed 2025-04-15 | $548.00K 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | $139.00K 10-Q · filed 2024-11-13 | $274.00K derived: sum of 2 quarters · filed 2024-11-13 | $406.00K 10-Q · filed 2024-11-13 | $535.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $135.00K 10-Q · filed 2024-08-14 | $268.00K 10-Q · filed 2024-08-14 | $396.00K derived: sum of 3 quarters · filed 2024-08-14 | $534.00K derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $132.00K 10-Q · filed 2024-05-09 | $261.00K derived: sum of 2 quarters · filed 2024-05-09 | $399.00K derived: sum of 3 quarters · filed 2024-05-09 | $538.00K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $267.00K derived: sum of 2 quarters · filed 2024-03-27 | $406.00K derived: sum of 3 quarters · filed 2024-03-27 | $542.00K 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $138.00K 10-Q · filed 2023-11-08 | $277.00K derived: sum of 2 quarters · filed 2023-11-08 | $413.00K 10-Q · filed 2023-11-08 | $412.91K 10-Q · filed 2022-11-02 | $546.34K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $139.00K 10-Q · filed 2023-08-09 | $275.00K 10-Q · filed 2023-08-09 | $274.73K 10-Q · filed 2022-08-11 | $408.34K derived: sum of 3 quarters · filed 2023-08-09 | $533.34K derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $136.00K 10-Q · filed 2023-05-10 | $136.13K 10-Q · filed 2022-05-12 | $269.34K derived: sum of 2 quarters · filed 2023-05-10 | $394.34K derived: sum of 3 quarters · filed 2023-05-10 | $510.34K derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $133.34K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $258.34K derived: sum of 2 quarters · filed 2023-03-15 | $374.34K derived: sum of 3 quarters · filed 2023-03-15 | $501.00K 10-K · filed 2023-03-15 | $501.36K 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $125.00K 10-Q · filed 2022-11-02 | $241.00K derived: sum of 2 quarters · filed 2022-11-02 | $367.66K 10-Q · filed 2022-11-02 | $492.39K derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $116.00K 10-Q · filed 2022-08-11 | $242.49K 10-Q · filed 2022-08-11 | $243.00K 10-Q · filed 2021-08-10 | $367.39K derived: sum of 3 quarters · filed 2022-08-11 | $489.39K derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $126.90K 10-Q · filed 2022-05-12 | $127.00K 10-Q · filed 2021-05-10 | $251.39K derived: sum of 2 quarters · filed 2022-05-12 | $373.39K derived: sum of 3 quarters · filed 2022-05-12 | $493.39K derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $124.50K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $246.50K derived: sum of 2 quarters · filed 2022-03-11 | $366.50K derived: sum of 3 quarters · filed 2022-03-11 | $484.57K 10-K/A · filed 2022-03-11 | ||||
| 2020-09-30 | $122.00K 10-Q · filed 2021-11-08 | $242.00K derived: sum of 2 quarters · filed 2021-11-08 | $360.07K 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $120.00K 10-Q · filed 2021-08-10 | $238.00K 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $118.00K 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | $452.05K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |